uploads///medicine _

Pfizer’s Valuation Post-4Q17 Earnings

By

Mar. 15 2018, Published 1:47 p.m. ET

A look at Pfizer’s valuation

Pfizer (PFE) reported revenue of $13.7 billion in 4Q17, a 1% rise compared to $13.6 billion in 4Q16. Pfizer surpassed Wall Street analysts’ consensus estimate for its EPS (earnings per share) in the quarter, reporting EPS of $0.62 compared to the consensus of $0.56.

Pfizer missed analysts’ consensus estimate for revenue. It reported revenue of ~$13.70 billion compared to the estimate of ~$13.72 billion in 4Q17.

The above chart compares the estimates for EPS and reported EPS for Pfizer since 1Q16.

Article continues below advertisement

Forward PE

The PE multiple represents what one share of a company can buy for an equity investor. Pfizer was trading at a forward PE multiple of ~12.2x on March 15, 2018, compared to the industry average of ~15.1x. Its competitors Merck & Co. (MRK), Eli Lilly (LLY), and Bristol-Myers Squibb (BMY) were trading at higher forward PE multiples of 13.0x, 15.7x, and 19.4x, respectively.

Forward EV-to-EBITDA

On a capital-structure-neutral basis, Pfizer is currently trading at a forward EV-to-EBITDA multiple of ~10.7x as of March 15, 2018, much lower than the industry average of ~12.5x. Merck & Co. is trading at a lower forward EV-to-EBITDA multiple of 10.6x, while Eli Lilly and Bristol-Myers Squibb are trading at forward EV-to-EBITDA multiples of 12.5x and 16.3x, respectively.

The iShares US Pharmaceuticals ETF (IHE) has 8.6% of its total holdings in Pfizer, 7.4% in Merck & Co., 5.4% in Eli Lilly, and 7.0% in Bristol-Myers Squibb.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.